These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Double-blind controlled trial of prostacyclin in cerebral infarction. Martin JF; Hamdy N; Nicholl J; Lewtas N; Bergvall U; Owen P; Syder D; Holroyd M Stroke; 1985; 16(3):386-90. PubMed ID: 3890279 [TBL] [Abstract][Full Text] [Related]
9. [Treatment of the peripheral vascular diseases with prostaglandin]. Miyauchi Y Nihon Rinsho; 1994 Aug; 52(8):2182-6. PubMed ID: 7933609 [TBL] [Abstract][Full Text] [Related]
10. A double blind placebo controlled trial of intravenous prostacyclin (PGI2) in 108 patients with ischaemic peripheral vascular disease. Virgolini I; Fitscha P; Linet OI; O'Grady J; Sinzinger H Prostaglandins; 1990 Jun; 39(6):657-64. PubMed ID: 2115186 [TBL] [Abstract][Full Text] [Related]
11. Hemodynamic, platelet and clinical responses to prostacyclin in unstable angina pectoris. Théroux P; Latour JG; Diodati J; Léger-Gauthier C; Morissette D; Bosch X; de Lara J; Waters D Am J Cardiol; 1990 May; 65(16):1084-9. PubMed ID: 2109927 [TBL] [Abstract][Full Text] [Related]
12. Cicaprost, an orally active prostacyclin analogue: its effects on platelet aggregation and skin blood flow in normal volunteers. Belch JJ; McLaren M; Lau CS; Mackay IR; Bancroft A; McEwen J; Thompson JM Br J Clin Pharmacol; 1993 Jun; 35(6):643-7. PubMed ID: 8329292 [TBL] [Abstract][Full Text] [Related]
13. [Treatment of acute cerebral infarction with PGI2--evaluating the clinical effect and observation of dynamic changes in plasma TXB2 and 6-keto PGF1 alpha levels]. Zhao J Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1991 Jun; 24(3):138-40, 186-7. PubMed ID: 1889319 [TBL] [Abstract][Full Text] [Related]
14. The pharmacological effects of cicaprost, an oral prostacyclin analogue, in patients with Raynaud's syndrome secondary to systemic sclerosis--a preliminary study. Lau CS; McLaren M; Saniabadi A; Scott N; Belch JJ Clin Exp Rheumatol; 1991; 9(3):271-3. PubMed ID: 1879086 [TBL] [Abstract][Full Text] [Related]
15. Prostaglandin E1 incorporated in lipid microspheres in the treatment of peripheral vascular diseases and diabetic neuropathy. Hoshi K; Mizushima Y; Kiyokawa S; Yanagawa A Drugs Exp Clin Res; 1986; 12(8):681-5. PubMed ID: 3757764 [TBL] [Abstract][Full Text] [Related]
16. Orally active prostacyclin analogue beraprost sodium in patients with chronic kidney disease: a randomized, double-blind, placebo-controlled, phase II dose finding trial. Koyama A; Fujita T; Gejyo F; Origasa H; Isono M; Kurumatani H; Okada K; Kanoh H; Kiriyama T; Yamada S BMC Nephrol; 2015 Oct; 16():165. PubMed ID: 26475266 [TBL] [Abstract][Full Text] [Related]
17. Beraprost: a review of its pharmacology and therapeutic efficacy in the treatment of peripheral arterial disease and pulmonary arterial hypertension. Melian EB; Goa KL Drugs; 2002; 62(1):107-33. PubMed ID: 11790158 [TBL] [Abstract][Full Text] [Related]
18. Vasorelaxant effect of isocarbacyclin methyl ester incorporated into lipid microspheres on isolated canine arteries. Sawada K; Aoki K; Katsuura Y; Tanabe H; Kiyoki M; Araki H Arzneimittelforschung; 1995 Sep; 45(9):985-8. PubMed ID: 7488318 [TBL] [Abstract][Full Text] [Related]